MEDS 10-Q filed 2026-11-13 | Key takeaways
MEDS filed its 10-Q; the most relevant disclosure change is expanded Business combinations: Completed Helomics Corporation acquisition on September 11, 2026 for $1.9M (636,328 shares at $0.90/share plus $1.36M convertible note), expanding into precision oncology and laboratory services. Acquired net assets of $1.9M including goodwill of $1.6M.
Key takeaways
Nine-month 2026 revenues of $6.0M declined 72% year-over-year from $21.7M, reflecting significant decline in Wellgistics distribution revenue due to liquidity constraints.
Helomics Corporation acquired September 11, 2026 for $1.9M (stock and convertible note), expanding into precision oncology laboratory services.
No single customer exceeded 10% of accounts receivable as of September 30, 2026, down from two customers representing 25% and 18% as of December 31, 2025.
Cash declined to $476K from $2.5M at June 30, 2026; working capital deficit of $31.3M with $23.7M of debt due within twelve months raises substantial going concern doubt.
Name changed from Wellgistics Health, Inc. to DataMeds AI, Inc. effective July 22, 2026; subsidiary rebranded to Corexa Health, Corexa Pharmacy, and Corexa Tech & Hub.
Nasdaq compliance regained for minimum bid price ($1.00) and stockholders' equity ($2.5M) requirements following reverse stock split and equity transactions.
Key metrics
Disclosure changes
- Business combinations
Completed Helomics Corporation acquisition on September 11, 2026 for $1.9M (636,328 shares at $0.90/share plus $1.36M convertible note), expanding into precision oncology and laboratory services. Acquired net assets of $1.9M including goodwill of $1.6M.
First acquisition contributing to new service line; Helomics reported no revenue and $41K loss post-acquisition. - Asset acquisitions
Healthstar Technologies LLC (51% owned) acquired KareHub platform intellectual property for $2.0M (30,000 shares at closing plus $1.89M variable share obligation), recognizing $3.9M of intellectual property and $1.9M non-controlling interest.
New technology platform acquisition through 51%-owned subsidiary; 7-year useful life amortization. - Debt extinguishments
September 2026 settlement with Wellgistics sellers extinguished $17.5M principal and $1.7M accrued interest for $450K cash and repurchase of 364,099 shares, resulting in $19.1M gain on debt extinguishment.
Largest single item driving Q3 net income; eliminates $17.5M of long-term debt. - Going concern
Management concluded substantial doubt exists about the company's ability to continue as a going concern for twelve months following issuance, with $23.7M of debt due within twelve months including $20.3M New Notes maturing May 27, 2027, and cash of only $476K.
Liquidity position deteriorated significantly despite debt extinguishment; debt quantum increased due to May 2026 refinancing. - Subsidiary restructuring
Company name changed from Wellgistics Health, Inc. to DataMeds AI, Inc. effective July 22, 2026; subsidiaries renamed to Corexa Health, LLC, Corexa Pharmacy, LLC, and Corexa Tech & Hub, LLC on August 10, 2026.
Corporate rebranding reflects strategic shift toward AI and technology platforms. - Non-controlling interest
First presentation of non-controlling interest of $1.9M in condensed consolidated balance sheets, representing Kare Hub's 49% membership interest in Healthstar Technologies, LLC.
New minority interest from Healthstar asset acquisition; net loss attributed to NCI was $54K.
Primary source
TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.
Open SEC filingFollow MEDS in real time
Get material earnings, filing, IR, and earnings-call alerts by email.